Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin

Published:2013-12-19 Issue:12 Volume:8 Page:e84927
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wei Huafeng,Zhao Likun,Li Wei,Fan Kexing,Qian Weizhu,Hou Sheng,Wang Hao,Dai Min,Hellstrom Ingegerd,Hellstrom Karl Erik,Guo Yajun

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference44 articles.

1. Cancer statistics, 2013;R Siegel;CA Cancer J Clin,2013

2. The molecular biology of epithelial ovarian cancer;A Leary;Bull Cancer,2012

3. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;RF Ozols;J Clin Oncol,2003

4. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum;AY Ali;Ann N Y Acad Sci,2012

5. Immunotherapy for ovarian cancer: what's next?;LE Kandalaft;J Clin Oncol,2011

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells;Journal for ImmunoTherapy of Cancer;2024-04

2. Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols;Nature Cancer;2024-03-01

3. Study on Molecular Mechanism of AGGF1 Neutralizing Antibody Combined with Anti CTLA-4 Antibody in Suppressing the Growth of Mouse Melanoma;Advances in Clinical Medicine;2024

4. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1;Cancer Immunology, Immunotherapy;2023-10-05

5. Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications;Frontiers in Immunology;2023-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3